专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO2014161046A1 METHODS OF TREATING DISEASES CHARACTERIZED BY EXCESSIVE WNT SIGNALLING 审中-公开
标题翻译：治疗由过度WNT信号表征的疾病的方法
公开(公告)号：WO2014161046A1
公开(公告)日：2014-10-09
申请号：PCT/AU2014/000370
申请日：2014-04-04
申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
发明人： ERNST, Matthias Robert Walter , PHESSE, Toby James , BUCHERT, Michael , STUART, Emma Charlotte
IPC分类号： A61K31/00 , A61K31/519 , A61K31/7088 , A61K39/395 , A61P35/00
CPC分类号： A61K31/506 , A61K31/505 , A61K31/519 , A61K31/5377 , A61K31/713
摘要： The present invention relates to a method of treating or preventing a disease characterized by excessive Wnt signalling, such as colorectal cancer, by administering a compound which inhibits the activity of one or more of JAK2, JAKl or TYK2.
摘要翻译：本发明涉及通过施用抑制JAK2，JAK1或TYK2中的一种或多种的活性的化合物来治疗或预防以Wnt信号传递为特征的疾病如结肠直肠癌的方法。

82. 发明申请

WO2014134728A1 METHODS AND GENES FOR NORMALIZATION OF GENE EXPRESSION 审中-公开
标题翻译：用于正常化基因表达的方法和基因
公开(公告)号：WO2014134728A1
公开(公告)日：2014-09-12
申请号：PCT/CA2014/050174
申请日：2014-03-06
申请人： UNIVERSITÉ DE MONTRÉAL , THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
发明人： SAUVAGEAU, Guy , MACRAE, Tara , SARGEANT, Tobias
IPC分类号： C12Q1/68 , C40B30/00 , G06F19/20
CPC分类号： G06F19/20 , C12Q1/6886 , C12Q2600/158
摘要： Novel genes exhibit minimal variation in expression level across different samples and which may be used as housekeeping genes for normalization of gene expression in quantitative gene expression measurements are disclosed. A novel method for the identification of housekeeping genes using whole Transcriptome Shotgun Sequencing (RNA-seq) is also disclosed.
摘要翻译：新基因在不同样品中表达水平的变化最小，可用作定量基因表达测定中基因表达标准化的管家基因。还公开了使用整个转录组霰弹枪测序（RNA-seq）鉴定管家基因的新方法。

83. 发明申请

WO2012151636A1 ACTIN BINDING AGENTS 审中-公开
标题翻译： ACTIN绑定代理
公开(公告)号：WO2012151636A1
公开(公告)日：2012-11-15
申请号：PCT/AU2012/000524
申请日：2012-05-11
申请人： BAUM, Jacob , GUNNING, Peter , THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
发明人： BAUM, Jacob , GUNNING, Peter
IPC分类号： C07K16/44 , A61K39/015 , A61P33/06
CPC分类号： C07K16/205 , C07K2317/33 , C07K2317/34 , C07K2317/76
摘要： The present invention relates generally to antibodies and fragments thereof which are capable of specifically binding apicomplexan actin. The invention also relates to an epitope of apicomplexan actin which can be used to raise such antibodies, and to screening methods for identifying other agents that are capable of binding specifically to apicomplexan actin. The invention further relates to methods of treating diseases caused by apicomplexan parasites.
摘要翻译：本发明一般涉及能够特异性结合apicomplexan肌动蛋白的抗体及其片段。本发明还涉及可用于产生这种抗体的复合物肌动蛋白的表位，以及用于鉴定能够特异性结合与apicomplexan肌动蛋白结合的其它试剂的筛选方法。本发明还涉及治疗由复合物寄生虫引起的疾病的方法。

84. 发明申请

WO2012045157A1 ARIH2 REGULATES DENDRITIC CELL ACTIVATION AND AUTOIMMUNITY 审中-公开
标题翻译： ARIH2调节细胞激活和自身免疫
公开(公告)号：WO2012045157A1
公开(公告)日：2012-04-12
申请号：PCT/CA2011/001122
申请日：2011-10-07
申请人： UNIVERSITY HEALTH NETWORK , WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , MAK, Tak W. , LIN, Amy Erica , PELLEGRINI, Marc
发明人： MAK, Tak W. , LIN, Amy Erica , PELLEGRINI, Marc
IPC分类号： C12N5/10 , A61K31/7088 , A61K38/17 , A61K39/39 , A61K39/395 , A61K47/48 , A61P31/04 , A61P35/00 , A61P37/06 , G01N33/48
CPC分类号： A61K39/0008 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0387 , A61K31/7105 , A61K2039/5154 , C12N9/93 , C12N15/8509 , G01N33/5044 , G01N33/68 , G01N2500/10 , G01N2800/042 , G01N2800/24 , G01N2800/50 , G01N2800/52 , G01N2800/7028 , G01N2800/7095
摘要： Arih2 negatively regulates dendritic cell (DC) activation and inhibits NFĸB signaling. Methods and compositions are provided for suppressing immune response, reducing chronic inflammation, treating autoimmune diseases, preventing diabetes and inhibiting dendritic cell activation by increasing the biological activity of Arih2. Also provided are methods and compositions for enhancing immune response, treating infections, treating cancer and enhancing DC activation by decreasing the biological activity of Arih2.
摘要翻译： Arih2负调节树突状细胞（DC）激活并抑制NFκB信号。提供了通过增加Arih2的生物活性来抑制免疫应答，减少慢性炎症，治疗自身免疫性疾病，预防糖尿病和抑制树突状细胞活化的方法和组合物。还提供了通过降低Arih2的生物活性来增强免疫应答，治疗感染，治疗癌症和增强DC活化的方法和组合物。

85. 发明申请

WO2011038469A1 SUPPRESSIVE AGENTS 审中-公开
标题翻译：抑制剂
公开(公告)号：WO2011038469A1
公开(公告)日：2011-04-07
申请号：PCT/AU2010/001299
申请日：2010-10-01
申请人： PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH , THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , MONASH UNIVERSITY , FINDLAY, Jock , KERR, Jeffrey , HUTT, Karla , SCOTT, Clare , STRASSER, Andreas , MICHALAK, Ewa
发明人： FINDLAY, Jock , KERR, Jeffrey , HUTT, Karla , SCOTT, Clare , STRASSER, Andreas , MICHALAK, Ewa
IPC分类号： A61P15/08
CPC分类号： A61K31/00
摘要： Methods of conserving fertility in a female subject are provided, comprising administering to a female or to oocytes ex vivo an agent which (i) suppresses PUMA expression or PUMA polypeptide activity; (ii) suppress PUMA and NOXA expression or PUMA and NOXA polypeptide activity; (iii) NOXA expression or NOXA polypeptide activity; or (iv) suppresses TP63 expression or TP63 activity. In some embodiments, the female is or will be under cancer treatment; is diagnosis as perimenopausal or menopausal or at risk of developing same within a predetermined time span; or is undergoing IVF. In some embodiments, the agent binds to PUMA, NOXA , or TP63 nucleic acid and suppress PUMA, NOX A or TP63 expression. In other embodiments the agents bind to PUMA, NOXA or TP63 and suppress PUMA, NOXA or TP63 polypeptide activity.
摘要翻译：提供了保护女性受试者生育能力的方法，包括向雌性或卵母细胞离体施用（i）抑制PUMA表达或PUMA多肽活性的试剂; （ii）抑制PUMA和NOXA表达或PUMA和NOXA多肽活性; （iii）NOXA表达或NOXA多肽活性; 或（iv）抑制TP63表达或TP63活性。在一些实施方案中，雌性或正在进行癌症治疗; 诊断为围绝经期或绝经期或处于预定时间范围内发展相同的风险; 或正在接受体外受精。在一些实施方案中，所述试剂与PUMA，NOXA或TP63核酸结合并抑制PUMA，NOXA或TP63表达。在其它实施方案中，所述试剂结合PUMA，NOXA或TP63并抑制PUMA，NOXA或TP63多肽活性。

86. 发明申请

WO2010148422A1 COMPOUNDS AND METHODS FOR TREATING PARASITIC INFESTATIONS 审中-公开
标题翻译：化合物和方法治疗PARASITIC INFESTATIONS
公开(公告)号：WO2010148422A1
公开(公告)日：2010-12-29
申请号：PCT/AU2010/000514
申请日：2010-05-04
申请人： WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , FAIRLIE, Doug , LEE, Erinna Faith , COLMAN, Peter Malcolm
发明人： FAIRLIE, Doug , LEE, Erinna Faith , COLMAN, Peter Malcolm
IPC分类号： C07K14/435 , A61P33/10 , G01N33/68 , A61K31/495 , A61P33/12 , G06F17/50 , A61K38/17 , C07D295/04 , A61K39/395 , C40B30/04
CPC分类号： C07K14/43559 , A61K31/495 , A61K38/00 , C07D295/112 , C07K2299/00 , C12Q1/18 , G01N2500/00 , Y02A50/423
摘要： The present invention relates to compounds and methods for treating or preventing parasitic infestations. In particular, the present invention relates to compounds which antagonize, or down-regulate the production of, pro-survival proteins in parasites which cause diseases such as Schistosomiasis.
摘要翻译：本发明涉及用于治疗或预防寄生虫感染的化合物和方法。特别地，本发明涉及在引起诸如血吸虫病等疾病的寄生虫中拮抗或下调生存蛋白质的化合物。

87. 发明申请

WO2010015032A1 METHODS OF TREATING AND PREVENTING GLUCOSE TOXICITY 审中-公开
标题翻译：治疗和预防葡萄糖毒性的方法
公开(公告)号：WO2010015032A1
公开(公告)日：2010-02-11
申请号：PCT/AU2009/001003
申请日：2009-08-05
申请人： ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH , WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , STRASSER, Andreas , MCKENZIE, Mark , THOMAS, Helen , ALLISON, Janette , KAY, Tom
发明人： STRASSER, Andreas , MCKENZIE, Mark , THOMAS, Helen , ALLISON, Janette , KAY, Tom
IPC分类号： A61K39/395 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61P3/10 , A61P9/10 , A61P13/12 , A61P25/02
CPC分类号： C12N15/1135 , A61K31/7088 , A61K31/713 , C07K16/22
摘要： The present invention relates to a method for treating and/or preventing a disease associated with glucose toxicity in a subject which comprises administering to the subject a compound that reduces the level of Bim, PUMA and/or Bax activity in a cell of the subject. Furthermore, provided is a method for culturing cells susceptible to exposure to high concentrations of glucose, which comprises delivering to the cells, or progenitor cells thereof, a compound that reduces the level of Bim, PUMA and/or Bax activity in the cells.
摘要翻译：本发明涉及用于治疗和/或预防与受试者相关的葡萄糖毒性相关疾病的方法，其包括向受试者施用降低受试者细胞中Bim，PUMA和/或Bax活性水平的化合物。此外，提供了培养容易暴露于高浓度葡萄糖的细胞的方法，其包括向细胞或其祖细胞递送降低细胞中Bim，PUMA和/或Bax活性水平的化合物。

88. 发明申请

WO2009052561A1 COMPOSITIONS AND METHODS FOR MANIPULATING AN IMMUNE RESPONSE 审中-公开
标题翻译：用于控制免疫应答的组合物和方法
公开(公告)号：WO2009052561A1
公开(公告)日：2009-04-30
申请号：PCT/AU2008/001558
申请日：2008-10-22
申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , LIN, Ming-Lee , ZHAN, Yifan , VILLADANGOS, Jose, A. , SUTHERLAND, Robyn, M. , LEW, Andrew, M. , CARRINGTON, Emma, Margarete , KLUCK, Ruth, Margaret
发明人： LIN, Ming-Lee , ZHAN, Yifan , VILLADANGOS, Jose, A. , SUTHERLAND, Robyn, M. , LEW, Andrew, M. , CARRINGTON, Emma, Margarete , KLUCK, Ruth, Margaret
IPC分类号： A61K38/16 , A61P35/00 , A61P31/00 , A61P37/00
CPC分类号： A61K38/17
摘要： A method for reducing antigen presentation by one or more antigen presenting cells is described. The method comprises the steps of introducing an exogenous apoptosis-inducing agent into the cytosol of the one or more antigen presenting cells, and triggering apoptosis of the one or more antigen presenting cells by an apopto sis-triggering complex that includes the exogenous apoptosis-inducing agent and an endogenous apoptosis-inducing agent. Reduction in antigen presentation by antigen presenting cells in accordance with the method described, can result in a reduced immune response, a reduction in cross-presentation of antigens to one or more CD8 + T- cells, a reduction in interleukin 12 expression, and/or a reduction in toll-like receptor 3 expression.
摘要翻译：描述了通过一种或多种抗原呈递细胞减少抗原呈递的方法。该方法包括将外源细胞凋亡诱导剂引入一种或多种抗原呈递细胞的胞质溶胶中，并通过包含外源凋亡诱导的凋亡引发复合物引发一种或多种抗原呈递细胞的凋亡的步骤药物和内源性细胞凋亡诱导剂。根据所述方法减少抗原呈递细胞的抗原呈递可导致免疫应答降低，抗原向一个或多个CD8 + T细胞的交叉呈递减少，白细胞介素12表达的降低和/或收缩样受体3表达的减少。

89. 发明申请

WO2009026660A1 DENDRITIC CELL MARKER AND USES THEREOF 审中-公开
标题翻译： DENDRITIC CELL MARKER及其用途
公开(公告)号：WO2009026660A1
公开(公告)日：2009-03-05
申请号：PCT/AU2008/001294
申请日：2008-08-29
申请人： WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , THE BURNET INSTITUTE , LAHOUD, Mireille Hanna , PROIETTO, Anna Irene , CAMINSCHI, Irina , SHORTMAN, Ken , LEW, Andrew Mark , WU, Li , WRIGHT, Mark Dexter
发明人： LAHOUD, Mireille Hanna , PROIETTO, Anna Irene , CAMINSCHI, Irina , SHORTMAN, Ken , LEW, Andrew Mark , WU, Li , WRIGHT, Mark Dexter
IPC分类号： C07K16/28 , C12N5/22 , C12N15/09 , G01N33/53
CPC分类号： C07K14/705 , A61K39/385 , A61K39/39 , A61K47/6849 , A61K51/1027 , A61K2039/6056 , C07K14/7056 , C07K16/18 , C07K2317/73 , C12N15/8258 , G01N33/5005 , G01N33/5047 , G01N2333/42 , G01N2333/4724 , G06F19/16 , Y02A50/412
摘要： The present invention relates to the identification of proteins located on the cell surface of dendritic cells or precursors thereof, particularly antigen presenting dendritic cells. In particular, the present invention relates to compounds such as antibodies that bind these proteins. These compounds can be used to detect and/or enrich a subset of dendritic cells or precursors thereof. These compounds can also be used to target antigens to dendritic cells or precursors thereof to modulate a humoral and/or T cell mediated immune response to an antigen, or used to target cytotoxic agents to dendritic cells or precursors thereof involved in diseased states.
摘要翻译：本发明涉及鉴定位于树突状细胞或其前体的细胞表面上的蛋白质，特别是抗原呈递树突状细胞。特别地，本发明涉及化合物，例如结合这些蛋白质的抗体。这些化合物可用于检测和/或富集树突状细胞或其前体的子集。这些化合物也可用于将抗原靶向树突状细胞或其前体，以调节对抗原的体液和/或T细胞介导的免疫应答，或用于将细胞毒剂靶向涉及患病状态的树突状细胞或其前体。

90. 发明申请

WO2009021289A1 POTASSIUM CHANNEL INHIBITORS 审中-公开
标题翻译：钾通道抑制剂
公开(公告)号：WO2009021289A1
公开(公告)日：2009-02-19
申请号：PCT/AU2008/001181
申请日：2008-08-14
申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , BACHEM BIOSCIENCES, INC. , NORTON, Raymond, Stanley , SMITH, Brian, John , PENNINGTON, Michael
发明人： NORTON, Raymond, Stanley , SMITH, Brian, John , PENNINGTON, Michael
IPC分类号： C07K14/00 , A61K38/16 , A61P37/06
CPC分类号： C07K14/43504 , A61K38/00
摘要： The present invention relates to a peptide or a pharmaceutically acceptable salt thereof comprising amino acid sequence 1: R 1 xaa 29 xaa 28 c 1 xaa1xaa 2 xaa 3 xaa 4 xaa 5 xaa 6 xaa 7 xaa 8 c 2 xaa 9 xaa 10 xaa 11 xaa 12 c 3 xaa 13 xaa 14 xaa 15 xaa 16 xaa 17 xaa 18 xaa 19 xaa 20 xaa 21 xaa 22 c 4 xaa 23 xaa 24 xaa 25 c 5 xaa 26 xaa 27 c 6 -R 2 SEQ ID NO:1 wherein xaa 17 is a positively charged D amino acid residue; xaa 18 is an aromatic D amino acid residue; xaa 1 to xaa 16 , xaa 19 to xaa 27 are each independently selected from any D amino acid residue; xaa 28 and xaa 29 are independently absent or are selected from any D amino acid residue; R 1 is hydrogen or is an amino acid residue, an N- terminal capping group or an oligopeptide optionally capped with an N- terminal capping group; R 2 is hydrogen or is an amino acid residue, a C -terminal capping group or an oligopeptide optionally capped with a C -terminal capping group; wherein each of c 1 and c 6 are independently selected from D-cysteine, D- homocysteine, D-penicillamine or D-selenocysteine and ci is linked to c 6 through a disulfide, diseleno or sulfide-selenium bond; or both c 1 and c 6 are D-amino acid residues having a side chain double bond and the side chains of ci and c 6 are linked to form a dicarba bond; and each of c 2 to c 5 are independently selected from D-cysteine and D-selenocysteine and c 2 is linked to c 4 and c 3 is linked to c 5 through disulfide, diseleno or sulfide-selenium bonds.
摘要翻译：本发明涉及包含氨基酸序列1：R1 xaa29xaa28c1xaa1xaa2xaa3xaa4xaa5xaa6xaa7xaa8c2xaa9xaa10xaa11xaa12c3xaa13xaa14xaa15xaa16xaa17xaa18xaa19xaa20xaa21xaa22c4xaa23xaa24xaa25c5xaa26xaa27c6-R2的肽或其药学上可接受的盐，其中xaa17是带正电荷的D氨基酸残基; xaa18是芳香族D氨基酸残基; xaa1至xaa16，xaa19至xaa27各自独立地选自任何D氨基酸残基; xaa28和xaa29独立地不存在或选自任何D氨基酸残基; R1是氢或是氨基酸残基，N-末端封端基团或任选地用N-末端封端基团封端的寡肽; R2是氢或是氨基酸残基，C-末端封端基团或任选用C-末端封端基团封端的寡肽; 其中c1和c6各自独立地选自D-半胱氨酸，D-高半胱氨酸，D-青霉胺或D-硒代半胱氨酸，ci通过二硫键，硒或硫化物硒键与c6连接; 或者c1和c6都是具有侧链双键的D-氨基酸残基，ci和c6的侧链连接形成二碳键; c2至c5各自独立地选自D-半胱氨酸和D-硒代半胱氨酸，c2与c4连接，c3通过二硫键，硒或硫化物硒键与c5连接。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式